Immune Responsiveness to the Immunodominant Recombinant Envelope Epitopes of Human T Lymphotropic Virus Types I and II in Diverse Geographic Populations

Buckner, Cindy M.; Roberts, Clifford R.; Foung, Steven K. H.; Lipka, James J.; Reyes, Gregory R.; Hadlock, Kenneth G.; Chan, Lily; Góngora-Biachi, Renán A; Hjelle, Brian; Lal, Renu B.

doi:10.1093/infdis/166.5.1160

Cited by 40 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HTLV-I is endemic in the southern part of Japan, sub-Saharan Africa, Brazil and the Caribbean area [8]. A high prevalence of HTLV-II infections is reported in subsets of Indians living in the USA [9], Panama [10] and Brazil [11], and in individuals of several African countries [12][13][14][15]. In contradistinction to Europe [16], where HTLV-II infection is rare among blood donors, more than half of the HTLVpositive donations in the USA are infected with HTLV-II [17].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a New HTLV‐I/II Polymerase Chain Reaction

Vrielink¹,

Zaaijer

Cuypers

et al. 1997

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of a New HTLV‐I/II Polymerase Chain Reaction

Vrielink¹,

Zaaijer

Cuypers

et al. 1997

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…All of the serum or plasma samples were tested for HTLV antibodies by 3 different screening assays,12 as described previously: an enzyme‐linked immunosorbent assay (ELISA) (Diagnostic Biotechnology, Singapore) containing disrupted HTLV‐1 and 2 recombinant peptides, one specific for HTLV‐1 gp46 (amino acids 162–209) (MTA1) and the second specific for HTLV‐2 gp46 (amino acids 162–205) (K55); a particle agglutination (PA) assay (Fujirebio Inc., Tokyo, Japan); and an immunofluorescence (IF) assay with an HTLV‐1 (MT2)‐ or HTLV‐2 (C19)‐producing cell line. Furthermore, all samples were submitted to an HTLV‐1/2 confirmatory test using a Western blot (immunoblot) (WB) containing disrupted HTLV‐1, a recombinant protein (rgp21) reacting with both HTLV‐1 and HTLV‐2 antibodies, and the 2 gp46 peptides MTA1 and K55 12, 81, 82. HTLV antibody titers were determined by submitting serial dilutions of the plasma samples or the sera to the PA and IF assays.…”

Section: Methodsmentioning

confidence: 99%

Means, responders, and meaning: Evaluation of clinical trials in osteoarthritis

Schnitzer

2003

Arthritis & Rheumatism

View full text Add to dashboard Cite

When fluidized by a gas, some agglomerated fine and ultrafine particles display a regime of uniform, nonbubbling fluidization known as agglomerate particulate fluidization (APF). The agglomeration of micrometric sized particles, or simple pre‐existing agglomerates in the case of nanoparticles, is governed by the balance between hydrodynamic shear forces and interparticle attractive forces. From this balance the theoretical scaling law Bog ∼ kD+2 has been derived, where Bog, the granular Bond number, is the ratio of the interparticle attractive force to particle weight, k is the ratio of agglomerate to particle size, and D is the fractal dimension. In the experimental program the behavior of gas‐fluidized beds of fine and ultrafine particles as affected by the use of neon and nitrogen as fluidizing gas is studied. The experimental results indicate that there is no relevant distinction between the sizes of agglomerates fluidized with the different gases as theoretically predicted. However, it is seen that the relatively small increment of gas viscosity opens up a new window of highly expanded agglomerate particulate fluidization (APF) behavior with a delayed onset of bubbling. For a sufficiently high‐gas viscosity, and/or smaller particle size, full suppression of the bubbling regime is observed. For nanoparticles exhibiting agglomerate bubbling fluidization (ABF) behavior, where bed expansion is small, and bubbling occurs soon after minimum fluidization, we also observe a delayed onset of bubbling when fluidizing with a gas of higher viscosity. © 2007 American Institute of Chemical Engineers AIChE J, 54: 86–103, 2008

show abstract

“…A high prevalence of HTLV-II infections is reported in subsets of Indians living in the USA [9], Panama [10] and Brazil [11], and in individuals of several African countries [12][13][14][15]. In contradistinction to Europe [16], where HTLV-II infection is rare among blood donors, more than half of the HTLVpositive donations in the USA are infected with HTLV-II [17].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a New HTLV-I/II Polymerase Chain Reaction

Cuypers¹,

Poel²,

Vrielink³

et al. 1997

Vox Sanguinis

View full text Add to dashboard Cite

Aim: Evaluation of a qualitative HTLV-I/Il DNA polymerase chain reaction (PCR) test for the detection of HTLV-I/II DNA (Roche Diagnostic Systems, Branchburg, N.J., USA) in various panels. Methods: The panels consisted of fresh EDTA blood samples from blood donors who were anti-HTLV-I/II ELISA repeatably reactive: 53 were Western blot (WB) positive, 228 were WB indeterminate and 15 were WB negative. Elevent ELISA-negative blood donors were used as negative controls. Furthermore, specimens from 1 HTLV-II-infected intravenous drug user and from 1 HTLV-II-infected blood donor were included in the panel. Peripheral blood lymphocytes were prepared by red blood cell lysis with the Roche washing solution and stored at <-23 °C until processing. Amplification products were analyzed with the HTLV-I/II detection kit. Results: All 53 anti-HTLV-I/II ELISA- and WB-positive samples and both HTLV-II-positive samples tested positively by PCR. All 228 anti-HTLV-I/II ELISA-positive and WB-indeterminate, all 15 ELISA-positive and WB-negative and all 11 ELISAnegative control samples tested negative by PCR. Conclusion: The Roche Amplicor HTLV-I/II test is a simple test, suitable for the confirmation of HTLV-I and -II infection in individuals with indeterminate or positive WB patterns.

show abstract

Immune Responsiveness to the Immunodominant Recombinant Envelope Epitopes of Human T Lymphotropic Virus Types I and II in Diverse Geographic Populations

Cited by 40 publications

References 14 publications

Evaluation of a New HTLV‐I/II Polymerase Chain Reaction

Evaluation of a New HTLV‐I/II Polymerase Chain Reaction

Means, responders, and meaning: Evaluation of clinical trials in osteoarthritis

Evaluation of a New HTLV-I/II Polymerase Chain Reaction

Contact Info

Product

Resources

About